Digital Enablers of Nanomedicine: Pharmaceutical Software Across the Lifecycle of Nanotechnology‑Based Drug Products

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 28 | 01 | Page :
    By

    Mohd. Wasiullah,

  • Piyush Yadav,

  • Aman Saroj,

  1. Principal, Department of pharmacy, Prasad Institute of Technology, Jaunpur,, Uttar Pradesh, India
  2. Head, Department of pharmacy, Prasad Institute of Technology, Jaunpur,, Uttar Pradesh, India
  3. Scholar,department of pharmacy, Prasad Institute of Technology, Jaunpur,, Uttar Pradesh, India

Abstract

Nanotechnology‑based drug products have rapidly evolved from laboratory concepts to clinically relevant therapies, yet their development is constrained by complex design variables, stringent quality requirements, and emerging regulatory expectations specific to nanomaterials. Pharmaceutical software now plays a central role in the nanomedicine lifecycle, enabling in silico design of nano‑carriers, simulation of nano–bio interactions, control of nanoscale quality attributes during manufacturing, and systematic tracking of safety signals in real‑world use. Integrated digital platforms link molecular modelling, process analytical technology, and regulatory data management so that researchers can optimise particle size, surface chemistry, and release profiles while documenting compliance with guidelines for nanomaterials and environmental safety. At the same time, artificial intelligence, digital twins, and advanced analytics are beginning to transform how nanoformulations are scaled up, monitored, and evaluated for long‑term risk, including nanotoxicological and sustainability considerations. This review discusses the main categories of pharmaceutical software relevant to nanomedicine—design and simulation tools, nano‑focused manufacturing and quality systems, clinical and pharmacovigilance platforms, and regulatory and supply‑chain solutions—and highlights opportunities and challenges in building a robust digital infrastructure for safe, effective, and sustainable nanotechnology‑based therapies.

Keywords: Keywords: nanomedicine, pharmaceutical software, nano‑drug delivery, nanomaterials, quality by design, process analytical technology, digital twins, pharmacovigilance, regulatory compliance.

How to cite this article:
Mohd. Wasiullah, Piyush Yadav, Aman Saroj. Digital Enablers of Nanomedicine: Pharmaceutical Software Across the Lifecycle of Nanotechnology‑Based Drug Products. Nano Trends – A Journal of Nano Technology & Its Applications. 2026; 28(01):-.
How to cite this URL:
Mohd. Wasiullah, Piyush Yadav, Aman Saroj. Digital Enablers of Nanomedicine: Pharmaceutical Software Across the Lifecycle of Nanotechnology‑Based Drug Products. Nano Trends – A Journal of Nano Technology & Its Applications. 2026; 28(01):-. Available from: https://journals.stmjournals.com/nts/article=2026/view=237708


References

  1. Rzigalinski, B.A., Strobl, J.S. (2019). Cadmium-containing nanoparticles: perspectives on pharmacology and toxicology of quantum dots. Nanomedicine, 14(8), 1011–1025.​
  2. Etheridge, M.L., Campbell, S.A., Erdman, A.G., Haynes, C.L., Wolf, S.M., McCullough, J. (2013). The big picture on nanomedicine: the state of investigation and approved nanomedicine products. Nanomedicine, 9(1), 1–14.​
  3. Ventola, C.L. (2017). Progress in nanomedicine: approved and investigational nanodrugs. P&T, 42(12), 742–755.​
  4. Duncan, R., Gaspar, R. (2011). Nanomedicine(s) under the microscope. Molecular Pharmaceutics, 8(6), 2101–2141.​
  5. Anselmo, A.C., Mitragotri, S. (2019). Nanoparticles in the clinic: an update. Bioengineering & Translational Medicine, 4(3), e10143.​
  6. Wicki, A., Witzigmann, D., Balasubramanian, V., Huwyler, J. (2015). Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. Journal of Controlled Release, 200, 138–157.​
  7. Lu, W., Zhang, G., Zhang, R. et al. (2016). Tumor site–targeted nanomedicines: progress and perspectives. Nano Today, 11(2), 168–186.​
  8. Desai, N. (2012). Challenges in development of nanoparticle-based therapeutics. AAPS Journal, 14(2), 282–295.​
  9. Dobrovolskaia, M.A., Shurin, M., Shvedova, A.A. (2016). Current understanding of interactions between nanoparticles and the immune system. Toxicology and Applied Pharmacology, 299, 78–89.​
  10. Fadeel, B., Farcal, L., Hardy, B. et al. (2018). Advanced tools for the safety assessment of nanomaterials. Nature Nanotechnology, 13(7), 537–543.​
  11. Li, M., Al-Jamal, K.T., Kostarelos, K., Reineke, J. (2010). Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano, 4(11), 6303–6317.​
  12. Zhao, J., Stenzel, M.H. (2018). Entry of nanoparticles into cells: the importance of nanoparticle properties. Polymer Chemistry, 9(3), 259–272.​
  13. Oksel, C., Ma, C.Y., Lau, C.H. et al. (2015). Nanomaterial dose metrics: selection, calculation and application in nano-QSAR. Nanotoxicology, 9(12), 1509–1519.​
  14. Fourches, D., Pu, D., Tassa, C. et al. (2010). Quantitative nanostructure–activity relationship modeling. ACS Nano, 4(10), 5703–5712.​
  15. Lin, Z., Monteiro-Riviere, N.A., Riviere, J.E. (2015). A physiologically based pharmacokinetic model for polyethylene glycol–coated gold nanoparticles of different sizes in adult mice. Nanotoxicology, 9(2), 169–179.​
  16. Ijjeh, Y., et al. (2025). Quality by digital design for accelerated sustainable pharmaceutical development. Journal of Pharmaceutical Sciences, 114(3), 456–472.​
  17. Maharjan, R., et al. (2025). Transformative roles of digital twins from drug discovery to biopharmaceutical manufacturing. Journal of Pharmaceutical Innovation, 20(2), 233–248.​
  18. Iswariya, V.T., et al. (2024). Digital twins in drug discovery: a paradigm shift shaping future pharmaceuticals. International Journal of Pharmaceutical Sciences and Nanotechnology, 17(5), 3124–3135.​
  19. Wold, S., Esbensen, K., Geladi, P. (1987). Principal component analysis. Chemometrics and Intelligent Laboratory Systems, 2(1–3), 37–52.​
  20. Kourti, T. (2021). Process analytical technology and chemometrics: applications in complex pharmaceutical processes. Analytica Chimica Acta, 1160, 338370.​
  21. Lionberger, R.A., Lee, S.L., Lee, L.M., Raw, A., Yu, L.X. (2008). Quality by design: concepts for ANDAs. AAPS Journal, 10(2), 268–276.​
  22. Yu, L.X., Amidon, G., Khan, M.A. et al. (2014). Understanding pharmaceutical quality by design. AAPS Journal, 16(4), 771–783.​
  23. Jiang, W., Lionberger, R., Yu, L.X. (2011). In vitro and in silico approaches to characterize nanotechnology-based drug products. AAPS Journal, 13(2), 176–182.​
  24. Locatelli, E., Franchini, M.C. (2012). Biodegradable nanoparticles in nanomedicine: achievements and new challenges. Therapeutic Delivery, 3(5), 607–621.​
  25. Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release, 160(2), 117–134.​
  26. (2018). FDA’s Approach to Regulation of Nanotechnology Products. U.S. Food and Drug Administration, Nanotechnology Programs.​
  27. European Medicines Agency. (2020). Reflection Paper on Nanotechnology-Based Medicinal Products for Human Use. EMA/CHMP guidelines.​
  28. Kosemund, K., et al. (2017). Regulatory challenges of nanomedicines and their follow-on versions: a European regulatory perspective. Nanomedicine, 12(3), 245–260.​
  29. Lamprou, D.A. (2018). Emerging technologies for diagnostics and drug delivery in the fight against COVID-19 and other pandemics. Expert Opinion on Drug Delivery, 15(11), 1061–1064.​
  30. Bregoli, L., Movia, D., Gavigan-Imedio, J.D. et al. (2016). Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomedicine, 11(7), 1017–1020.​
  31. Harpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., Ryan, P., Shah, N.H. (2012). Performance of pharmacovigilance signal-detection algorithms for the FDA Adverse Event Reporting System. Clinical Pharmacology & Therapeutics, 93(6), 539–546.​
  32. Morita, T., Ando, Y., Kato, A. et al. (2016). Safety database design for nanomedicines: capturing nano-specific safety information. Regulatory Toxicology and Pharmacology, 81, 132–140.​
  33. World Health Organization. (2018). A Coordinated Global Research Roadmap: Nanotechnology and Human Health. WHO Technical Report.​
  34. Global Pharma Academy. (2024). Pharmacovigilance vs Clinical Data Management: Key Roles in Drug Safety. Global Pharma Academy blog article.​
  35. Zink, R., Marchenko, O., Bretz, F. (2020). Adaptive clinical trials guided by software analytics. Statistics in Medicine, 39(10), 1423–1435.
Ahead of Print Subscription Review Article
Volume 28
01
Received 07/02/2026
Accepted 17/02/2026
Published 27/02/2026
Publication Time 20 Days
56

Login


My IP

PlumX Metrics